ChemoCentryx to Participate in Two Upcoming Investor Conferences

Rhea-AI Summary

ChemoCentryx (Nasdaq: CCXI) announced that its CEO, Thomas J. Schall, will participate in two upcoming investor conferences. The first is the 2021 Virtual Wells Fargo Healthcare Conference, with a fireside chat scheduled for September 9 at 4:40 p.m. ET. The second is the H.C. Wainwright 23rd Annual Global Investment Conference, featuring an on-demand presentation available from September 13 at 6:00 a.m. ET. Investors can access live webcasts and replays via the company's website. ChemoCentryx is focused on developing treatments for inflammatory and autoimmune diseases and cancer.

SAN CARLOS, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will participate in two upcoming investor conferences:

• 2021 Virtual Wells Fargo Healthcare Conference
  Fireside Chat Thursday, September 9 at 4:40 p.m. Eastern Time

• H.C. Wainwright 23rd Annual Global Investment Conference
  On-demand presentation available beginning Monday, September 13 at 6:00 a.m. Eastern Time
  

Live audio webcasts of the Wells Fargo fireside chat, as well as the on-demand H.C. Wainwright presentation can be accessed through the Investors section of the Company's website at www.ChemoCentryx.com. Replays of both the Wells Fargo and H.C. Wainwright presentations will be available on the Company's website for two weeks following the respective presentation dates.

About ChemoCentryx
ChemoCentryx is a biopharmaceutical company developing new medications for inflammatory and autoimmune diseases and cancer. ChemoCentryx targets the chemokine and chemoattractant systems to discover, develop and commercialize orally-administered therapies. ChemoCentryx’s lead drug candidate, avacopan (CCX168), successfully completed a pivotal Phase III trial in ANCA-associated vasculitis and is in late stage clinical development for the treatment of severe Hidradenitis Suppurativa and C3 glomerulopathy (C3G).

ChemoCentryx also has early stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases and in cancer.

Contacts:

Susan M. Kanaya                                        
Executive Vice President,                                         
Chief Financial and Administrative Officer
investor@chemocentryx.com                               

Media:
Stephanie Tomei
408.234.1279
media@chemocentryx.com

Investors:
Lee Roth, Burns McClellan
212.213.0006
lroth@burnsmc.com

FAQ

When will Thomas J. Schall participate in the Wells Fargo Healthcare Conference?

Thomas J. Schall will participate in the Wells Fargo Healthcare Conference on September 9 at 4:40 p.m. ET.

What is the date for the on-demand presentation at the H.C. Wainwright Conference?

The on-demand presentation at the H.C. Wainwright Conference will be available starting September 13 at 6:00 a.m. ET.

How can I access the webcasts for the investor conferences of ChemoCentryx?

Live audio webcasts and replays for the investor conferences can be accessed through the Investors section of ChemoCentryx's website.

What is the main focus of ChemoCentryx's drug development?

ChemoCentryx focuses on developing new medications for inflammatory and autoimmune diseases as well as cancer.

What is the lead drug candidate of ChemoCentryx and what condition does it target?

ChemoCentryx's lead drug candidate is avacopan (CCX168), which targets ANCA-associated vasculitis.